BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Prognosis
347 results:

  • 1. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma.
    Tang H; Miao X; Yu C; Chai C; Su Y; Li L; Yi J; Ye Z; Miao L; Wang Z; Zhang H; Xu H; Zhou W
    Sci Rep; 2024 Apr; 14(1):9259. PubMed ID: 38649719
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multiple pathological fractures and muscle atrophy caused by a parathyroid carcinoma with postoperative hungry bone syndrome: A case report.
    Liu Q; Zhang Y; Ma D; Gengzhi H; Maimaiti Y; Chen Q; Ma Z
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2047. PubMed ID: 38577726
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
    Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
    Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.
    Qiu X; Lu C; Sha H; Zhu Y; Kong W; Tong F; Wang Q; Meng F; Liu B; Du J
    Front Immunol; 2024; 15():1210859. PubMed ID: 38361920
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Social Vulnerability Association with Thyroid cancer Disparities in the United States.
    Fei-Zhang DJ; Verma R; Arimoto R; Lawrence AS; Chelius DC; Patel UA; Smith SS; Sheyn AM; Rastatter JC
    Thyroid; 2024 Feb; 34(2):225-233. PubMed ID: 38069566
    [No Abstract]    [Full Text] [Related]  

  • 6. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
    Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
    Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.
    Xu C; Zhu M; Wang Q; Cui J; Huang Y; Huang X; Huang J; Gai J; Li G; Qiao P; Zeng X; Ju D; Wan Y; Zhang X
    J Nanobiotechnology; 2023 Nov; 21(1):410. PubMed ID: 37932752
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
    Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
    J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Co-Occurrence of Germline Genomic Variants and Copy Number Variations in Hereditary Breast and Colorectal cancer Patients.
    Côrtes L; Basso TR; Villacis RAR; Souza JDS; Jørgensen MMA; Achatz MI; Rogatto SR
    Genes (Basel); 2023 Aug; 14(8):. PubMed ID: 37628631
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Is unicentric familial papillary thyroid microcarcinoma different from multicentric?
    Ríos A; Ruiz-Pardo J; Balaguer-Román A; Puñal JA; Moreno P; Mercader E; Ferrero E; Morlán MA; Martín J; Durán M; Bravo JM; Casanova D; Salvador-Egea MP; Torregrosa NM; Exposito-Rodríguez A; Martínez-Fernández G; Carrión AM; Vidal O; Herrera F; Ruiz-Merino G; Rodríguez JM
    Endocrine; 2023 Dec; 82(3):613-621. PubMed ID: 37490266
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic cancer.
    Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
    Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
    Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
    ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Discordance Between Conventional and Detailed Lymph Node Analysis in Resected, Node-negative Pancreatic or Ampullary Adenocarcinomas and Association With Adverse Survival Outcomes: A Single-institution Analysis.
    Elshami M; Ammoun AK; Mneimneh WS; Stitzel HJ; Hue JJ; Wu VS; Kyasaram RK; Shanahan J; Musonza T; Ammori JB; Hardacre JM; Winter JM; ElHag M; Ocuin LM
    Ann Surg; 2023 Dec; 278(6):e1204-e1209. PubMed ID: 37051926
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
    Köbel M; Kang EY; Weir A; Rambau PF; Lee CH; Nelson GS; Ghatage P; Meagher NS; Riggan MJ; Alsop J; Anglesio MS; Beckmann MW; Bisinotto C; Boisen M; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; Deen S; El-Bahrawy MA; Elishaev E; Erber R; Fereday S; ; Fischer A; Gayther SA; Barquin-Garcia A; Gentry-Maharaj A; Gilks CB; Gronwald H; Grube M; Harnett PR; Harris HR; Hartkopf AD; Hartmann A; Hein A; Hendley J; Hernandez BY; Huang Y; Jakubowska A; Jimenez-Linan M; Jones ME; Kennedy CJ; Kluz T; Koziak JM; Lesnock J; Lester J; Lubiński J; Longacre TA; Lycke M; Mateoiu C; McCauley BM; McGuire V; Ney B; Olawaiye A; Orsulic S; Osorio A; Paz-Ares L; Ramón Y Cajal T; Rothstein JH; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Steed H; Storr SJ; Talhouk A; Traficante N; Wang C; Whittemore AS; Widschwendter M; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido Dos Reis FJ; Campbell I; Cook LS; DeFazio A; Doherty JA; Fasching PA; Fortner RT; García MJ; Goodman MT; Goode EL; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Kommoss S; Le ND; Martin SG; Menon U; Modugno F; Pharoah PD; Schildkraut JM; Sieh W; Staebler A; Sundfeldt K; Swerdlow AJ; Ramus SJ; Brenton JD
    J Pathol Clin Res; 2023 May; 9(3):208-222. PubMed ID: 36948887
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Diabetes mellitus impacts on expression of DNA mismatch repair protein pms2 and tumor microenvironment in pancreatic ductal adenocarcinoma.
    Pan X; Mizukami H; Hara Y; Yamada T; Yamazaki K; Kudoh K; Takeuchi Y; Sasaki T; Kushibiki H; Igawa A; Hakamada K
    J Diabetes Investig; 2023 Jan; 14(1):132-144. PubMed ID: 36453157
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid cancer and Distant Metastases in the United States, 1992-2018.
    Wilhelm A; Conroy PC; Calthorpe L; Shui AM; Kitahara CM; Roman SA; Sosa JA
    Thyroid; 2023 Jan; 33(1):63-73. PubMed ID: 36413032
    [No Abstract]    [Full Text] [Related]  

  • 17. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels.
    Ono Y; Inoue Y; Ito H; Sasaki T; Takeda T; Ozaka M; Sasahira N; Hiratsuka M; Matsueda K; Oba A; Sato T; Saiura A; Takahashi Y
    HPB (Oxford); 2023 Jan; 25(1):100-108. PubMed ID: 36280425
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Biological behavior of familial papillary thyroid microcarcinoma: Spanish multicenter study.
    Ríos A; Rodríguez MA; Puñal JA; Moreno P; Mercader E; Ferrero E; Ruiz-Pardo J; Morlán MA; Martín J; Durán-Poveda M; Bravo JM; Casanova D; Egea MPS; Torregrosa NM; Exposito-Rodríguez A; Martínez-Fernández G; Carrión AM; Vidal O; Herrera F; Ruiz-Merino G; Rodríguez JM
    Langenbecks Arch Surg; 2022 Dec; 407(8):3631-3642. PubMed ID: 36251077
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for advanced pancreatic and periampullary adenocarcinoma.
    Thosani N; Cen P; Rowe J; Guha S; Bailey-Lundberg JM; Bhakta D; Patil P; Wray CJ
    Sci Rep; 2022 Oct; 12(1):16516. PubMed ID: 36192558
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis.
    Debernardi S; Blyuss O; Rycyk D; Srivastava K; Jeon CY; Cai H; Cai Q; Shu XO; Crnogorac-Jurcevic T
    Int J Cancer; 2023 Feb; 152(4):769-780. PubMed ID: 36093581
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 18.